FindTrial
Sign In

Crenolanib besylate

DRUG4 trials

Sponsors

Arog Pharmaceuticals, Inc.

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesFLT3-ITD MutationFLT3/TKD MutationPDGFR-Alpha D842VPDGFRA Gene Amplification

Phase 1

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
CompletedNCT02400281
Arog Pharmaceuticals, Inc.Acute Myeloid Leukemia
Start: 2015-09-30End: 2020-07-15Updated: 2024-07-03

Phase 2

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
CompletedNCT01657682
Arog Pharmaceuticals, Inc.Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Start: 2012-10-31End: 2019-04-30Updated: 2023-11-30
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
CompletedNCT02400255
Arog Pharmaceuticals, Inc.Acute Myeloid Leukemia
Start: 2015-09-30End: 2022-05-31Updated: 2023-12-18

Unknown Phase

Individual Patient Compassionate Use of Crenolanib
NCT03620318
Arog Pharmaceuticals, Inc.FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFRA Gene Amplification +1
Updated: 2024-08-09

Related Papers

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
Blood2024-11-053 citations
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
2020-12-07111 citations
Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant
Blood2018-11-296 citations
Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
Journal of Clinical Oncology2016-05-20101 citations
Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).
Journal of Clinical Oncology2014-05-2025 citations